COMPASS Pathways plc — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Compass reported two positive Phase 3 trials for COMP360 (synthetic psilocybin) in treatment-resistant depression showing rapid onset and durable benefit through 6+ months. NDA rolling submission underway with final submission expected Q4 2026; commercial launch targeted H1 2027 pending FDA approval and DEA rescheduling. Cash position of $433.3M as of June 30, 2026 funds operations into 2028; net loss of $162.6M for H1 2026 (vs. $56.3M prior year) driven primarily by $74.7M warrant fair-value adjustments.
Why this rating
Phase 3 success and regulatory momentum are material for a ~$257M biotech; approval would be transformational. But approval is not assured; DEA rescheduling remains uncertain. Event is significant but not yet a business guarantee.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.